NCT04127981 is a NA clinical trial of 18F-FDG PET + Dexa Scan in Cancer Cachexia, sponsored by Olivia Newton-John Cancer Research Institute.

Who is sponsoring NCT04127981?

NCT04127981 is sponsored by Olivia Newton-John Cancer Research Institute.

What drugs are being tested in NCT04127981?

Interventions in NCT04127981: 18F-FDG PET + Dexa Scan.

What condition does NCT04127981 study?

NCT04127981 studies Cancer Cachexia.

Is NCT04127981 still recruiting?

NCT04127981 is currently status unknown. Last updated 23 March 2023.

Last reviewed 2023-03-23 · How we verify

NCT04127981

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Medical Imaging of Cachexia

Status unknown NA Last updated 23 March 2023

What this trial tests

NA trial testing 18F-FDG PET + Dexa Scan in Cancer Cachexia in 40 participants. Status unknown.

Timeline

28 March 2019

Primary endpoint
28 December 2023

28 December 2023

Quick facts

Lead sponsor	Olivia Newton-John Cancer Research Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	28 March 2019
Primary completion	28 December 2023
Estimated completion	28 December 2023
Sites	1 location across Australia

Drugs / interventions tested

18F-FDG PET + Dexa Scan

Conditions studied

Cancer Cachexia — all drugs for Cancer Cachexia →

Sponsor

Olivia Newton-John Cancer Research Institute

Who can join

18 and older, any sex, with Cancer Cachexia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot trial using 18F-FDG PET and DXA scans to determine whether these investigations are objective tools to assess cachexia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy.
Cao Z, Burvenich IJ, Zhao K, Senko C, et al · · 2022 · cited 6× · PMID 36428623 · DOI 10.3390/cancers14225533
Targeting Fn14 as a therapeutic target for cachexia reprograms the glycolytic pathway in tumour and brain in mice.
Burvenich IJG, Osellame LD, Rigopoulos A, Huynh N, et al · · 2024 · cited 4× · PMID 39060375 · DOI 10.1007/s00259-024-06836-1

Verify or expand the search:

Other recruiting trials for Cancer Cachexia

Currently open trials in the same condition.

NCT07237464 — To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Health · Phase 1 · recruiting
NCT07072728 — Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder · Phase 2 · recruiting
NCT06898255 — A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia · Phase 1 · recruiting
NCT06868849 — A Study of JMT203 in Patients With Cancer Cachexia · Phase 1 · recruiting
NCT05915325 — Physical Training for Elderly Cancer Patients With Cachexia · NA · active not recruiting

Other Olivia Newton-John Cancer Research Institute trials

Trials by the same sponsor.

NCT05788081 — Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. · Phase 2 · active not recruiting
NCT05182931 — A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) · Phase 2 · unknown
NCT04969887 — Combination Immunotherapy in Rare Cancers Under InvesTigation · Phase 2 · active not recruiting
NCT04297748 — Bioimaging Study of 89Zr-M7824 in NSCLC · Phase 1, PHASE2 · terminated
NCT03374943 — A Trial of KB004 in Patients With Glioblastoma · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04127981 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Olivia Newton-John Cancer Research Institute
Last refreshed: 23 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04127981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing